The FTC and the Holy Grail: The Tipline for 31 March 2021

The Federal Trade Commission and Illumina are squaring off once again. This time, the agency is suing to block a vertical deal involving the world-leader in next-generation DNA sequencing. The commission alleges that Illumina’s purchase of Grail could allow it to raise prices or foreclose competition from rivals racing Grail to launch a new cancer screening test. Also in Tipline, Judge Amit Mehta encourages the Department of Justice to narrow its discovery demands from Google and the Antitrust Division files another round of criminal wage-fixing charges.

Get unlimited access to all Global Competition Review content